An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
Price : $35 *
At a glance
- Drugs Olendalizumab (Primary)
- Indications Antiphospholipid syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors Alexion Pharmaceuticals
- 14 Jun 2017 Status changed from completed to discontinued.
- 29 Mar 2017 This trial has been discontinued in UK (End date:2015-08-31) as per European Clinical Trials Database record.
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.